Summary of epidemiological effect measures on occupational risk of Lyme disease from 10 published studies of high or moderate use*
| Seroprevalence | Clinical prevalence | Clinical incidence | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Study group (%) | Control group (%) | OR (95% CI) | Study group (%) | Control group (%) | OR (95% CI) | Study group (%) | Control group (%) | RR (95% CI) |
| *NR, not reported; NA, not applicable; NC, not calculable; OR, odds ratio; RR, relative risk; †calculated with Intercooled Stata, version 6; ‡Data represents reported seroconversion. During the study, one case of Lyme disease was reported in the comparison group; §data were reported for two years, and thus represents a two-year cumulative incidence; ¶historical comparison group; **the prevalence of symptomatic disease was 1.9% for definite disease and 3.1% for probable disease; ††IgG and IgM activity to four different antigens were used, range reported is IgG only; ‡‡control data using IgG reactivity only, derived from Hauser et al 1998, table 123; §§lifetime prevalence; for Zhioua et al,22 the prevalence was for probable disease only. | |||||||||
| High use studies (n=2) | |||||||||
| Kuiper et al 199331 | 28 | 5.0 | 7.1 (3.2 to 15.8)† | 5.5 | NR | NA | 0.0 | NR | NA |
| Vos et al 199435 | NR | NR | NA | NR | NR | NA | 0.9‡ | 2.2‡ | 0.4 (0.1 to 1.2)† |
| Moderate use studies (n=8) | |||||||||
| Bowen et al 198448 | NR | NR | NA | NA | NA | NA | 3.8§ | 0.8§ | 4.9 (1.9 to 12.6)† |
| Chmielewska-Badora 199836 | 38.6 | 6 | 9.9 (2.6 to 36.8)† | 0.4 | 0.0 | NC | NA | NA | NA |
| 28.1 | 6.1 (1.8 to 20.4)† | ||||||||
| Fahrer et al 199840 | NR | NR | NA | NR | NR | NA | 0.8 | 0.8¶ | 1.0 |
| Fahrer et al 199141 | 26.1 | 3.9 | 8.6 (2.1 to 35.8)† | 1.9–3.1** | NR | NA | 0.8 | NR | NA |
| 6.0 | 5.5 (1.7 to 17.9)† | ||||||||
| Gustafson et al 199339 | 9 | 1 | 9.3 (3.6 to 24.2)† | 6.0§§ | 1.3§§ | 4.8 (1.1 to 20.6)† | NA | NA | NA |
| 9 | 0.9 (0.5 to 1.8)† | ||||||||
| Hauser et al 199823 | 41.0 to 44.8†† | 8‡‡ | 8.4 (4.4 to 15.9)† | NR | NR | NA | NA | NA | NA |
| Kuiper et al 199132 | 19.7 | 6.3 | 3.7 (1.5 to 9.7) | 6.0 | NR | NA | NA | NA | NA |
| Zhioua et al 199722 | 15.2 | 3.2 | 5.4 (0.7 to 40.7)† | 3.3§§ | NR | NA | NA | NA | NA |